Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment
Annals of Pharmacotherapy · 2026
DOI: 10.1177/10600280251358959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Pharmacotherapy, 2026. Verfasst von Richard Truong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA. Hauptthemen laut MEDLINE: Pulmonary Arterial Hypertension, Recombinant Fusion Proteins, Hypertension, Pulmonary, Antihypertensive Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objective: To review the pharmacology, pharmacokinetics, safety, and efficacy of sotatercept for the management of pulmonary arterial hypertension (PAH). Data Sources: A literature search in PubMed, EMBASE, and the National Institutes of Health Clinical Trials Registry ( http://www.clinicaltrials.gov ) was conducted from January 2009 to June 2025 using the keyword “ sotatercept .” Study Selection and Data Extraction: Phase II and III trials assessing sotatercept’s safety and efficacy were included. Initially, 796 trials were yielded, and 4 trials were included after application of inclusion criteria. Data Synthesis: The findings from this review indicate that sotatercept is an overall safe and effective option for improving PAH outcomes when added to established PAH pharmacotherapy. Trials found improvement in outcomes such as pulmonary vascular resistance, 6-minute walk distance, and a reduction in a composite outcome of all-cause death, lung transplantation, and hospitalization for worsening PAH. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs: Sotatercept targets a new pathway in PAH that directly addresses inappropriate cellular proliferation and the underlying pathophysiology in PAH. The benefit with sotatercept was found when added to background PAH therapy, but limitations for use include cost and need for reconstitution by the patient or caregiver. Conclusion and Relevance: Sotatercept offers a novel and effective approach to management of patients with PAH on background therapy. Additional data regarding long-term outcomes is needed—studies evaluating this are in progress.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, TX, USA.
- Anesthesiology and Critical Care, Houston Methodist Hospital, Houston, TX, USA.
ORCID-Profile: Shantera Davis, Natalie Rosario, Joshua Wollen, Yuanchen Wang, Elisabeth M Wang
Zitieren
APA
Truong, R., Davis, S., Rosario, N., Wollen, J., Johnson, C., Wang, Y., & Wang, E. M. (2026). Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280251358959
Vancouver
Truong R, Davis S, Rosario N, Wollen J, Johnson C, Wang Y, et al. Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment. Annals of Pharmacotherapy. 2026. doi:10.1177/10600280251358959
BibTeX
@article{Truong2026,
author = {Truong, Richard and Davis, Shantera and Rosario, Natalie and Wollen, Joshua and Johnson, Chad and Wang, Yuanchen and Wang, Elisabeth M},
title = {Sotatercept: A New Frontier in Pulmonary Arterial Hypertension Treatment},
journal = {Annals of Pharmacotherapy},
year = {2026},
doi = {10.1177/10600280251358959}
}
EUVIMED